Single® Single B Cell Antibody Discovery Technology
SmocMab® Fully Humanized Antibody Discovery Platform
Leveraging key advantages of SmocMab® mice, including diverse immune response profiles, high antibody affinity, and low immunogenicity, the SmocMab® Fully Humanized Antibody Development Platform effectively addresses core challenges in conventional antibody development: protracted timelines, elevated immunogenicity risks, and unstable success rates. It provides pharmaceutical R&D institutions with comprehensive end-to-end solutions.
More Flexible Partnering Frameworks
We offer a highly flexible, phased partnership model: clients can obtain samples directly after mouse immunization, or entrust us to continue with antibody discovery and move on to in vivo efficacy testing. From immunization to efficacy validation, each stage can be entered independently or connected seamlessly, fully meeting individual needs across different R&D stages and project timelines.
-
Antigen Preparation
Our professional team will conduct a customized project analysis based on your requirements, confirm the plan, and prepare the antigen.
-
Mouse Immunization
Mouse immunization is performed according to the client-confirmed immunization protocol established during prior consultations.
-
Antibody Discovery (Selectable)
We employ a multifaceted and multimodal approach to optimize antibody screening, striving to efficiently obtain high-quality target antibodies.
-
Antibody Affinity Validation (Selectable)
Comprehensive activity validation of the obtained antibodies.
-
In Vivo PD (Selectable)
Leveraging our extensive library of disease animal models, we conduct in vivo efficacy experiments for the developed antibodies.
More Diverse Antibody Discovery Solutions
We have built a diversified antibody discovery technology matrix spanning three pathways: hybridoma, single B cell, and phage display library. Hybridoma is mature and stable, single B cell is high-throughput and fast, and phage display excels at broad-spectrum screening. Each has its own strengths and complements the others. The optimal approach is selected flexibly based on target characteristics and project goals, significantly improving antibody discovery success rate and efficiency.
Hybridoma Technology
Phage Display Technology
More Streamlined One-Stop CRO Services
Leveraging an extensive animal model resource library and deep experience in preclinical in vivo efficacy evaluation, we provide one-stop CRO services from antibody discovery through efficacy validation. Once antibody discovery is complete, subsequent in vivo efficacy studies can begin directly without cross-platform handoffs, significantly shortening R&D timelines, reducing communication and transfer costs, and creating an efficient closed loop.
Integration of Extensive Animal Model Resources
Complemented by Multi-Platform CRO Services
More Precise Immunization Technology
Specifically designed to address the immunization challenges posed by highly homologous antigens, this approach effectively overcomes immune tolerance. Drawing on more than twenty years of experience in mouse gene editing, we can precisely design knockout strategies for the mouse homologous gene according to each target characteristic, eliminating self-recognition interference at the source. This enables SmocMab® fully humanized antibody mice to clearly recognize unique epitopes on human targets, eliciting stronger and more specific antibody responses and providing superior precision immunization support for antibody discovery against difficult, highly homologous targets.
Case Studies
High human–mouse homology across STEAP1 ECLs limits accessible epitopes
Immune tolerance limits STEAP1 responses in conventional immunization
KO strategy and proprietary immunogen design generate strong, target-specific titers
2,794 antibody sequences mapped across 650 clonotypes.
VH3/VH4 dominant immune response
Repertoire breadth/depth shown by CDR-H3 length distribution and V(D)J recombination patterns
Benchmark antibody: AMG509 (anti-steap1 IgG)
2,794 antibody sequences mapped across 650 clonotypes. Data represent a panel of 51 recombinant antibodies
Yellow and blue highlight: Internalization% range from 0.6- to 1.4-fold of AMG509 (anti-steap1 IgG)
Antibodies with different profiles can be used for different field : Internalizing for ADC while binding for TCE
High affinity binding with human PD-L1 comparable to Benchmark
High‑affinity human/cyno cross‑reactivity
Antibodies with high quality: 9/12 antibodies exhibit comparable interlization with BMK
Antibodies with high quality: 4/12 antibodies exhibit comparable blocking with BMK
BMK: Tecentriq-analogue
In vivo efficiency maily rely on blocking ability of antibodies.
Antibodies produced in SMOCmab mouse with high quality: Similar therapeutic effects with BMK without engineering modification of the V-region.
